# US 2022/0025436 A1 · Method and Kit For CCR2 Expression Profiling And Disease Stratification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025436 A1
- Document ID: US20220025436A1
- Status: Published application
- Kind: A1
- Application number: 17/382,240
- Filed: 2021-07-21
- Published: 2022-01-27
- Earliest claimed: 2020-07-21
- Assignees: Rutgers, The State University of New Jersey; Plumeria Therapeutics, Inc.
- Applicants: Rutgers, The State University of New Jersey; Plumeria Therapeutics, Inc.
- Inventors: Lei Yu; Thomas P. Richardson
- Web page: https://patentgrep.com/patent/US20220025436A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6851: Quantitative amplification
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods of treating disease include measuring a CCR2 profile of a patent, selecting a CCR2 antagonist based on the CCR2 profile of the patient, and administering the CCR2 antagonist to the patient. Methods for stratifying one or more patients for pain medication based on a CCR2 profile include measuring a CCR2 profile of one or more patients and partitioning the one or more patients into predetermined groups or subgroups based on the CCR2 profile of the one or more patients. Kits for performing the methods are also described.

## Claims

### Claim 1

A method for treating a disease in a patient in need thereof, the method comprising:
a) measuring a CCR2 profile of the patient, the CCR2 profile comprising a profile of CCR2 isoform A, CCR2 isoform B, or both, each CCR2 isoform comprising one or more respective polymorphisms;
b) selecting a compound based on the CCR2 profile of the patient, wherein the selected compound is an antagonist or agonist of at least one polymorphism identified from the measured CCR2 profile of the patient;
c) administering the selected compound to the patient.

### Claim at position 2

2-62. (canceled)

### Claim 63

A kit for generating a profile of CCR2A and CCR2B isoform expression levels for a human subject, the kit comprising:
a) one or more reagents for measuring a CCR2 profile of the patient, the CCR2 profile comprising a profile of CCR2 isoform A, CCR2 isoform B, or both, each CCR2 isoform comprising one or more respective polymorphisms, wherein the one or more reagents comprises a forward primer comprising a sequence selected from SEQ ID NOs: 7 through 15 and a reverse primer comprising a sequence selected from SEQ ID NOs: 16 through 28.

### Claim at position 4

64-68. (canceled)

### Claim 69

A method for generating a profile of CCR2A and CCR2B isoform expression levels for a human subject, the method comprising:
a) obtaining a sample from the human subject;
b) extracting RNA from the sample;
c) performing reverse transcription on the extracted RNA to generate cDNA;
d) amplifying the cDNA by performing polymerase chain reaction (PCR) by using a forward primer comprising a sequence selected from SEQ ID NOs: 7 through 15 and a reverse primer comprising a sequence selected from SEQ ID NOs: 16 through 28; and
e) quantifying CCR2A and CCR2B isoform expression levels from the amplified cDNA.

### Claim 70 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 7.

### Claim 71 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 8.

### Claim 72 (depends on 69)

The method of claim 69, wherein the reverse primer comprises SEQ ID NO: 18.

### Claim 73 (depends on 69)

The method of claim 69, wherein the reverse primer comprises SEQ ID NO: 17.

### Claim 74 (depends on 69)

The method of claim 69, wherein the reverse primer comprises SEQ ID NO: 22.

### Claim 75 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 7, and wherein the reverse primer comprises SEQ ID NO: 18.

### Claim 76 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 8, and wherein the reverse primer comprises SEQ ID NO: 18.

### Claim 77 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 8, and wherein the reverse primer comprises SEQ ID NO: 22.

### Claim 78 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 7, and wherein the reverse primer comprises SEQ ID NO: 17.

### Claim 79 (depends on 69)

The method of claim 69, wherein the forward primer comprises SEQ ID NO: 8, and wherein the reverse primer comprises SEQ ID NO: 17.

### Claim 80 (depends on 69)

The method of claim 69, wherein quantifying CCR2A and CCR2B isoform expression levels is by gel densitometry, blotting, nucleic acid hybridization, fluorescent in situ hybridization, reverse transcription-polymerase chain reaction, real-time polymerase chain reaction, microarray, nucleic acid sequencing, enzyme-linked immunosorbent assay (ELISA), or colorimetric quantification.

### Claim 81 (depends on 69)

The method of claim 69, wherein the sample is blood.

### Claim 82 (depends on 69)

The method of claim 69, wherein the sample is a bodily secretion.

### Claim 83 (depends on 82)

The method of claim 82, wherein the bodily secretion is saliva.

### Claim 84 (depends on 82)

The method of claim 82, wherein the bodily secretion is urine.

### Claim 85 (depends on 82)

The method of claim 82, wherein the bodily secretion is nasal mucosa.

### Claim 86 (depends on 82)

The method of claim 82, wherein the bodily secretion is vaginal mucosa.
